Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis

Table 1 Patients’ basic characteristics n (%)

	Total (n = 48365)	Compensated HBV group1 (n = 45683)	Decompensated cirrhosis group(n = 2682)	aP value
Sex (male)	32691 (67.6)	30881 (67.6)	1810 (67.5)	0.9214
Age (yr)	43.5 ± 12.3	43.0 ± 12.2	51.7 ± 11.5	< 0.0001
Nucleos(t)ide analog
Entecavir	20147 (41.7)	18644 (40.8)	1503 (56.0)	< 0.0001
Lamivudine	8411 (17.4)	7937 (17.4)	474 (17.7)	0.7105
Clevudine	3029 (6.3)	2898 (6.3)	131 (4.9)	0.0028
Lamivudine + adefovir	2525 (5.2)	2415 (5.3)	110 (4.1)	0.0084
Telbivudine	32 (0.1)	30 (0.1)	2 (0.1)	1.0000
Others	14221 (29.4)	13759 (30.1)	462 (17.2)	< 0.0001
Medication compliance
< 25%	12793 (26.5)	12045 (26.4)	748 (27.9)	0.0700
25%-50%	6067 (12.5)	5769 (12.6)	298 (11.1)	0.0229
50%-75%	7075 (14.6)	6686 (14.6)	389 (14.5)	0.8735
> 75%	22430 (46.4)	21183 (46.4)	1247 (46.5)	0.9835
Type of first decompensation
Refractory ascites	2022 (55.6)		2022 (55.6)
Varix bleeding	711 (19.6)		711 (19.6)
Hepatorenal syndrome	151 (4.2)		151 (4.2)
Hepatic encephalopathy	752 (20.7)		752 (20.7)

¹Patients with chronic hepatitis and with early compensated cirrhosis.

^aP < 0.05 by Chi-square and Student’s t-test. HBV: Hepatitis B virus.